Highbridge Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Highbridge Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100,000	Closed	-$4.77M	–	189
2019 Q1	$4.77M	Buy	+100,000	New	+$4.98M	0.15%	158
2018 Q3	–	Sell	-3,800	Closed	-$211K	–	518
2018 Q2	$211K	Sell	3,800 -196,200	-98%	-$10.6M	﹤0.01%	808
2018 Q1	$12.7M	Buy	+200,000	New	+$12.9M	0.2%	109
2017 Q4	–	Sell	-200,000	Closed	-$12.7M	–	1645
2017 Q3	$12.7M	Sell	200,000 -500,000	-71%	-$29.2M	0.19%	147
2017 Q2	$39M	Buy	700,000 +300,000	+75%	+$16.3M	0.58%	27
2017 Q1	$21.8M	Buy	+400,000	New	+$21.9M	0.32%	84
2016 Q4	–	Sell	-4,400	Closed	-$237K	–	1263
2016 Q3	$237K	Buy	+4,400	New	+$283K	﹤0.01%	1107
2015 Q4	–	Sell	-100,000	Closed	-$5.92M	–	1513
2015 Q3	$5.92M	Buy	+100,000	New	+$6.34M	0.09%	264
2014 Q3	–	Sell	-25,200	Closed	-$1.22M	–	1210
2014 Q2	$1.22M	Buy	+25,200	New	+$1.24M	0.01%	514
2013 Q4	–	Sell	-39,600	Closed	-$1.83M	–	1067
2013 Q3	$1.83M	Buy	+39,600	New	+$1.74M	0.02%	530

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's BMY Position: Q4 2018 in Review

Highbridge Capital Management sold out of Bristol-Myers Squibb (BMY) in Q4 2018, closing a stake of 30,734 shares — an estimated $1.91M sold.

Highbridge Capital Management first reported a position in BMY in Q2 2013 and held it in 13 quarters. The position peaked at $22.7M in Q1 2017. 1,765 funds tracked by Wall St. Rank hold BMY as of Q4 2018.

Highbridge Capital Management reported no remaining Bristol-Myers Squibb position as of Q4 2018 after selling out during the quarter.
Highbridge Capital Management sold 30,734 Bristol-Myers Squibb shares in Q4 2018, an estimated $1.91M.
Highbridge Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 13 quarters.
Highbridge Capital Management's Bristol-Myers Squibb position peaked at $22.7M in Q1 2017.
1,765 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2018.

Based on Highbridge Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.